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Abstract
Background and aims—Biomarkers and atherosclerosis imaging have been studied 
individually for association with incident cardiovascular disease (CVD); however, limited data 
exist on whether the biomarkers are associated with events with a similar magnitude in the 
presence of atherosclerosis. In this study, we assessed whether the presence of atherosclerosis as 
measured by carotid intima media thickness (cIMT) affects the association between biomarkers 
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known to be associated with coronary heart disease (CHD) and incident cardiovascular disease 
(CVD) in a primary prevention cohort.
Methods—8,127 participants from the ARIC study (4th visit, 1996–1998) were stratified as 
having minimal, mild, or substantial atherosclerosis by cIMT. Levels of C-reactive protein, 
lipoprotein-associated phospholipase A2, cardiac troponin T, N-terminal pro-brain natriuretic 
peptide, lipoprotein(a), cystatin C, and urine albumin to creatinine ratio were measured in each 
participant. Hazard ratios were used to determine the relationship between the biomarkers and 
incident CHD, stroke, and CVD in each category of atherosclerosis.
Results—While each of the biomarkers was significantly associated with risk of events overall, 
we found no significant differences noted in the strength of association of biomarkers with CHD, 
stroke, and CVD when analyzed by degree of atherosclerosis.
Conclusions—These findings suggest that the level of atherosclerosis does not significantly 
influence the association between biomarkers and CVD.
Keywords
Carotid intima media thickness; high sensitivity C-reactive protein; lipoprotein associated 
phospholipase A2; high sensitivity troponin T; NT-pro B-type natriuretic peptide; lipoprotein(a); 
cardiovascular disease; coronary heart disease; stroke
Introduction
Several biomarkers and atherosclerosis imaging measures have been evaluated for 
association with incident cardiovascular disease (CVD) and for value in predicting incident 
CVD. Imaging provides an assessment of atherosclerosis burden while biomarkers provide 
information related to the in vivo biochemical milieu.
Biomarkers associated positively with prevalent and incident cardiovascular disease 
including coronary heart disease and stroke include C-reactive protein (hs-CRP)1–5, 
lipoprotein-associated phospholipase A2 (LpPLA2)2,6,7, cardiac troponin T (cTnT)8, N-
terminal pro-brain natriuretic peptide (NT-proBNP)9, lipoprotein(a) (Lp(a))10–14, cystatin 
C15–18, and urine albumin to creatinine ratio9,19,20. Additionally, atherosclerosis as assessed 
using imaging techniques such as carotid intima media thickness (cIMT), carotid artery 
plaque, and coronary artery calcium measured on a computed tomography (CT) scan, have 
also been shown to be associated positively with CVD and to improve coronary heart disease 
risk prediction21–26. Although many of these modalities have been studied individually, 
limited data exist on whether all of the biomarkers are associated with events with a similar 
magnitude in the presence of atherosclerosis and whether these imaging measures and 
biomarkers interact with each other in the determination of cardiovascular risk.
The Cardiovascular Health Study (CHS) reported that a positive association between hs-
CRP and incident CV events was found only when atherosclerosis (as measured by c-IMT/ 
plaque) was present27. However, knowing whether other biomarkers are associated with 
CVD only in the presence of atherosclerosis is of interest and value in both clinical practice 
and in research as it may help us understand the implication if one test result is normal when 
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the other is abnormal. We sought to answer the question whether there is an interaction 
between biomarkers and levels of atherosclerosis as measured by carotid ultrasound on 
incident CVD. We hypothesized that the strength of the association between biomarkers and 
CVD would be significantly weaker in individuals with a lower burden of atherosclerosis, as 
defined by carotid IMT (cIMT) in the lowest quartile and absence of plaque, compared to 
those with a greater burden of atherosclerosis.
Materials and methods
Study design and study participants
The Atherosclerosis Risk in Communities (ARIC) study is a prospective study of the 
incidence of cardiovascular disease that includes 15,792 men and women between the ages 
of 45 and 64 who were recruited from four US communities (selected suburbs of 
Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina; 
Jackson, Mississippi) between the years of 1987 to 1989. Since the original visit, 4 
additional visits have been completed. The 4th visit of the ARIC study (1996–1998) formed 
the baseline for this analysis. The institutional review boards of all participating centers 
approved the ARIC study and all participants provided informed consent.
Additional description of the ARIC study design is published elsewhere28. Of the 15,792 
participants, we excluded those who did not participate in visit 4 (n= 4,136), those who 
described their race to be neither white or black (n= 31), blacks from the Minneapolis or 
Washington county cohorts (n= 38), participants with prevalent stroke or coronary heart 
disease (CHD) at visit 4 (n= 1,436), missing cIMT or plaque information at both visits 3 and 
4 (n= 1,469), missing biomarkers (n= 445), or missing CHD29,30 or stroke31 risk score at 
visit 4 (n= 120), which resulted in a remaining cohort of 8,127 individuals who were 
included in the final analysis. Prevalent CHD was defined as self-reported myocardial 
infarction prior to visit 1, silent myocardial infarction (diagnosed by electrocardiogram), 
ARIC-documented myocardial infarction, or coronary revascularization occurring between 
visits 1 and 4. Incident endpoints through 2012 assessed included CHD (defined as definite 
or probable myocardial infarction or fatal CHD), stroke (ischemic/thrombotic), which 
together comprised the CVD endpoint after visit 4. Methods for ascertainment and diagnosis 
of incident CVD events have been described previously32.
Cigarette smoking and the use of antihypertensive and lipid lowering medications were 
obtained from standardized questionnaires at visit 4. Hypertension was defined as systolic 
blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, prior diagnosis of 
hypertension by a physician, or the use of antihypertensive medications during the 2 weeks 
prior to participation. Diabetes was defined as a fasting plasma glucose level ≥126 mg/dL, a 
non-fasting plasma glucose level of ≥200 mg/dL, or a self-reported history of physician 
diagnosed diabetes or treatment for diabetes. Plasma total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), and triglycerides were measured using enzymatic 
measures. Low-density lipoprotein cholesterol (LDLC) was calculated using the Friedewald 
equation. Plasma hs-CRP was measured using a high sensitivity immunonephelometric 
assay using a BNII nephelometer (Siemens Healthcare Diagnostics, Deerfield, IL). The 
reliability coefficient in 421 blinded replicates was 0.99. Methods have been previously 
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described in the ARIC study33. Lp-PLA2 was measured by an automated Colorimetric 
Activity Method (CAM) assay (diaDexus Inc., South San Francisco, CA) using a Beckman 
Coulter (Olympus) AU400e autoanalyzer using a dual monoclonal antibody immunoassay 
that is standardized to recombinant Lp-PLA22,34. Interassay precision was assessed using 2 
controls of known concentration (low and high) in 40 separate assays; the interassay 
coefficients of variation were 12.7% and 9.6%, respectively. NT-proBNP was measured by 
using an electrochemiluminescent immunoassay on an automated Cobas e411 analyzer 
(Roche Diagnostics) with lower detection limit of 5 pg/mL. The reliability coefficient and 
the inter-assay coefficient of variation, were 1.00 and 9.9% and 1.00 and 6.7%, respectively. 
based on 418 blind-replicate quality control samples before and after removal of outliers 
(greater than 3 standard deviations). The interassay coefficient of variation, based on 83 
runs, at NT-proBNP concentrations of 121.6 pg/mL and 4059.1 pg/mL were 6.97% and 
6.76%, respectively. CTnT levels were measured with a high-sensitivity assay (Elecsys 
Troponin T; Roche Diagnostics, Indianapolis, Illinois, USA) using a Cobas e411 automated 
analyzer35. The lower and upper limits of detection of the cTnT assay are 3 and 10,000 ng/L, 
respectively, and the limit of quantitation is 13 ng/L. The reliability coefficient and 
interassay coefficient of variation, based on 418 blind quality control samples before and 
after removal of outliers (great than 3 standard deviations), were 0.98 and 23.1%, and 0.99 
and 15%, respectively. The interassay coefficient of variation, based on 103 runs, at cTnT 
concentrations of 29 ng/L and 2378 ng/L were 6.2% and 2.6%, respectively. Details on 
variability and interassay reliability have been previously described in the ARIC study36. 
Cystatin C was measured by a particle-enhanced immunonephelometric assay with a BNII 
nephelometer (Siemens Healthcare Diagnostics, Deerfield, Illinois, USA)37. The reliability 
coefficient for 421 blinded replicates was 0.65 (0.94 after removing 10 pairs of outliers). The 
coefficient of variation was 6.6%. Urine albumin creatinine ratio was calculated from a 
random urine sample. The Jaffe method was used to measure urine creatinine and the 
nephelometric method (measured either on the Dade Behring BN100 or Beckman Image 
Nephelometer) was used to measure urine albumin38. Lp(a) levels were measured at visit 4 
using an immunoturbidimetric assay using polyclonal antibodies directed against epitopes 
on apolipoprotein(a) (Denka Seiken, Coventry, United Kingdom)11,39. Other than the 
cholesterol markers and Lp(a) blood biomarker measurements were carried out using frozen, 
stored samples at a later date.
Ultrasound imaging
By design in the ARIC study, cIMT was performed in half of the participants at visit 3 and 
the remaining half at visit 4. Ultrasound images of the carotid arteries were obtained using a 
Biosound 2000II-SA ultrasound system and measured using standardized, centrally trained 
and certified readers. CIMT was assessed on both sides in 3 territories: the distal common 
carotid (1 cm proximal to the dilation of the carotid bulb), the carotid artery bifurcation (1 
cm proximal to the flow divider), and the proximal internal carotid arteries (a 1 cm section 
of the internal carotid artery immediately distal to the flow divider). We used the mean IMT 
value averaged across the six sites imputing any missing sites from the observed sites. 
Methods for imputation have been described previously40,41. The presence of plaque was 
determined by trained readers based on the presence or absence of two out of the following 
three criteria: abnormal wall thickness (defined as CIMT >1.5 mm), abnormal shape 
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(protrusion into the lumen and loss of alignment with adjacent arterial wall boundary), and 
abnormal wall texture (brighter echoes than adjacent boundaries). Since cIMT was measured 
in visits 3 and 4, cIMT was stratified by visit in addition to gender as <25, 25–75, and >75th 
percentile. Significant burden of sub-clinical atherosclerosis consisted of cIMT values >75th 
percentile and presence of plaque. Mild sub-clinical atherosclerosis category consisted of 
cIMT values between the 25th-75th percentile or presence of plaque. Minimal sub-clinical 
atherosclerosis category consisted of cIMT values <25th percentile and absence of plaque. 
All subjects in our cohort with cIMT >75th percentile had plaque present. To estimate the 
reliability of the IMT measurements, from 278 pairs of scans performed up to a year apart 
and the estimated correlation between the scans was 0.56 for the mean right common carotid 
ITM and 0.55 for the left common carotid IMT. Methodology for the cIMT measurement 
along with its variation and reproducibility has been previously described in the ARIC 
study42–47.
Statistical analyses
Biomarkers were modeled as continuous variables and were log transformed. A Cox 
proportional hazards model was developed to estimate the hazards ratio for each biomarker 
separately for the incident events of CHD, stroke, and CVD. Models were then rerun, 
stratified by cIMT and plaque presence into 3 categories: minimal (negligible), mild, and 
substantial atherosclerosis. Multiplicative interactions between the biomarker and 
atherosclerosis level were evaluated in the overall model, using cross-product terms, and the 
p-value for each interaction was determined using the Wald test. The Cox proportional 
hazards model were analyzed using two different sets of covariates. Model 1 adjusted for 
age at visit 4, race, and sex. For CHD, model 2 adjusted for the ARIC 10-year CHD risk 
score48. For stroke, model 2 adjusted for the ARIC 10-year stroke risk score31. For CVD, 
model 2 adjusted for variables used in CHD as well as the stroke risk scores. As 14.7% of 
participants had imputed values additional similar analyses were also done after exclusion of 
imputed values for each of the outcomes overall and across each of the IMT categories. 
Additionally, interactions between each biomarker and the presence of carotid artery plaque 
overall and in each of the 3 IMT categories was assessed for CHD, stroke, and CVD.
Results
The mean age of the study participants was 63 years, with 59% females and 81% whites at 
visit 4. Forty three percent of the participants had hypertension while 13% had diabetes 
(table 1). The mean BMI of the study population was 28.3 ± 5.3 kg/m2. During a median 
follow-up duration of 5448 days for CHD, 5458 for stroke, and 5424 for CVD, there were 
620 incident CHD events, 366 stroke events, and 924 CVD events in the cohort. The 
association between cIMT/plaque and CHD, stroke, and CVD events was significant even 
after adjusting for demographics and the ARIC 10-year CHD and stroke scores (p<0.005).
Most of the biomarkers were positively and independently associated with CHD, stroke, and 
CVD after both minimal (model 1) (model 1 graphs are shown in the supplemental material 
as supplemental figures 1–3) and additional adjustment for other risk factors (model 2). The 
hazards ratio (HR) for overall events for 1 unit increment of the log transformed variables 
Agarwala et al. Page 5
Atherosclerosis. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ranged from 1.04 (0.96, 1.13) for log lipoprotein(a) to 2.34 (1.72, 3.18) for log cystatin c 
after adjustment for other risk factors (model 2). Log LpPLA2 activity and log of Lp(a) did 
not demonstrate a significant association with stroke (hazards ratios are shown in 
supplemental tables 1–7). Log cystatin C demonstrated the strongest association with CHD 
(HR 2.34, 95% CI 1.72, 3.18), stroke (HR 2.32, 95% CI 1.53, 3.50), and CVD (HR 2.27 
95% CI 1.74, 2.95).
Incidence rates of CVD increased across levels of atherosclerosis (Table 2). Contrary to our 
hypothesis, the presence and degree of atherosclerosis did not significantly affect the 
associations in adjusted models between the biomarkers and CHD, stroke, or CVD (figures 
1–3), with no significant multiplicative interactions (p>0.05). For example, though log 
cystatin c was independently associated with CHD (HR 2.34, 95% CI 1.78, 3.18), when 
stratified by degree of atherosclerosis the hazard ratio was 1.62 for minimal atherosclerosis, 
2.38 for mild atherosclerosis, and 2.68 for substantial atherosclerosis with a p value for 
interaction of 0.72.
Of the participants used in the current analyses 14.7% had imputed cIMT values. After 
excluding participants with one or more imputed cIMT values (supplemental tables 9–11), 
the results were comparable to those in which the imputed cIMT values were included with 
the exception of log NT proBNP. The degree of atherosclerosis had a significant effect on 
CHD for log NT proBNP (HR 1.21, 95% CI 0.95, 1.54 for minimal atherosclerosis, HR 
1.21, 95% CI 1.10, 1.36 for mild atherosclerosis, and HR 1.59, 95% CI 1.35, 1.89 for 
substantial atherosclerosis, p for interaction is 0.04, supplemental tables 9–11). As there is 
some controversy about cIMT as a marker of atherosclerosis we also assessed presence of 
carotid plaque alone as a marker of atherosclerosis and investigated interactions between 
each biomarker and the presence of plaque overall and within each of the 3 IMT categories 
for each of the 3 outcomes (CHD, stroke, and CVD). The interaction between the 
biomarkers and plaque was not significant in any of the models (supplemental tables 12–14).
Discussion
In this prospective population-based study, we investigated whether the burden of 
atherosclerosis, as measured by cIMT/ presence of plaque, modifies the associations 
between biomarkers and incident CVD events. Contrary to our hypothesis, the positive 
associations of biomarkers with incident CVD were not stronger in the presence of 
substantial burden of atherosclerosis. Studies have demonstrated the presence of plaque even 
with normal cIMT suggesting the importance of assessing for carotid plaque48,49. In light of 
these findings, we assessed for interaction between biomarkers and the presence or of plaque 
overall and in each of the three cIMT categories, however, we did not find that the 
association between biomarkers and incident CVD was strengthened in the presence of 
plaque.
The development and manifestation of CVD is a complex process that encompasses a 
number of factors including plaque development, plaque burden, and the risk of rupture or 
vulnerability. Imaging techniques such as cIMT and coronary artery calcium score (CAC 
score) can be used to estimate the burden of atherosclerosis and have been shown to be 
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associated with and to improve prediction of incident CHD50–52. While there have been and 
continue to be efforts in imaging the components and activity of plaques, the value of these 
techniques in prediction of incident CVD is not yet established.
On the other hand, although biomarkers have been associated with CVD1–20 and provide a 
snapshot of the array of ongoing molecular processes, they generally do not provide 
specifics on the presence, composition, and stability of the plaques present. Hence we 
hypothesized that the presence of atherosclerosis may be required for the biomarkers to 
show an association with CVD. Our findings that biomarkers were positively associated with 
incident CVD whether or not atherosclerosis was present raise the question as to whether 
both of these variables, i.e. biomarkers and imaging (cIMT/plaque), which have previously 
shown independent association with incident events, may have additional value when 
combined; however this will need to be further explored. While the recent guidelines related 
to the management of hyperlipidemia53 will limit the additional value of combining 
biomarkers and imaging in CVD risk prediction (since the population where additional risk 
stratification could impact management has considerably decreased) further exploration of 
our results may be of value in the future design and conduct of clinical studies.
Strengths of the present study include the fact that it was conducted in a large, well-
characterized population based study whose stated goal is tracking and assessing 
cardiovascular disease incidence. We had information on several biomarkers and imaging, 
and the incident events were well characterized. Certain limitations also merit consideration: 
The meaning and value of cIMT that we included in our definition of atherosclerosis has 
been controversial. However, in the ARIC study both cIMT and plaque have been shown to 
be complementary and furthermore consensus documents such as the Mannheim consensus 
document and American Society of Echocardiography recommend the use of cIMT in 
addition to plaque and hence we used in our definition of atherosclerosis48,54,55. 
Furthermore, we did additional analyses to study the value of plaque alone and the results 
were for the most part the same. Another limitation is that by study design cIMT was 
performed at two different visits, three years apart. However we adjusted our analysis for the 
visit at which cIMT was done. Furthermore, although plaque information was utilized, it was 
only a qualitative assessment of presence or absence of plaque and no true quantification of 
plaque burden or assessment of characteristics of plaque, which would have been superior to 
test our hypothesis. However, technologies to accurately quantify plaque burden did not exist 
when ARIC ultrasound imaging was performed. Another consideration may be that 
atherosclerosis was assessed by ultrasound of the carotid and not CT scan based CAC. 
However, cIMT/ plaque presence has shown value in improving CHD risk prediction in the 
ARIC study40 and has been shown to better associate with stroke (an end point in our 
analysis) than CAC21. Therefore, while future studies may consider the use of CAC, our 
analysis has value on its own. Another potential limitation is that both the biomarkers and 
atherosclerosis indices were measured once and may have changed during the long follow-
up. Such misclassification would have tended to weaken observed risk factor associations 
and potentially limited our power to detect interactions with atherosclerosis. Finally, the lack 
of association of LpPLA2 and Lp(a) with some incident events, despite evidence of 
association in other studies including ARIC, must be considered. This may have been a 
result of the population included for this analysis, the longer follow-up time, or chance.
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In conclusion, several CAD biomarkers are associated with CVD regardless of the level of 
atherosclerosis, as measured by cIMT and presence of plaque.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Whether atherosclerosis as evidenced by carotid ultrasound (cIMT, 
plaque) is required for biomarkers to be associated with CVD was 
tested in the ARIC study
• Associations between biomarkers and CVD were not affected by 
degree of atherosclerosis
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Fig. 1. The relationship between biomarkers and incident coronary heart disease stratified by 
degree of atherosclerosis (Model 2), ARIC 1996 to 2012
p value is for the interaction term between each biomarker and degree of atherosclerosis.
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Fig. 2. The relationship between biomarkers and incident stroke stratified by degree of 
atherosclerosis (Model 2), ARIC 1996 to 2012
p value is for the interaction term between each biomarker and degree of atherosclerosis.
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Fig. 3. The relationship between biomarkers and incident cardiovascular events stratified by 
degree of atherosclerosis (Model 2), ARIC 1996 to 2012
p value is for the interaction term between each biomarker and degree of atherosclerosis.
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Table 1
Demographics and baseline characteristics
N 8,127
Age (years, mean ± SD) 62.5 ± 5.6
% Female 58.9%
% Caucasian 80.7%
% African American 19.3%
Hypertension (N) 43.3%
Diabetes (N) 13.4%
Total Cholesterol (mg/dL, mean ± SD) 202.2 ± 36.3
LDL-C (mg/dL, mean ± SD) 123.2 ± 33.1
HDL-C (mg/dL, mean ± SD) 51.4 ± 17.0
Triglycerides (mg/dL, mean ± SD) 141.1 ± 86.0
BMI (kg/m2, mean ± SD) 28.3 ± 5.3
% Smokers (current and ever) 56.7%
% Statin users 8.2%
Atherosclerosis. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Agarwala et al. Page 17
Table 2
Degree of atherosclerosis and incidence rate of CVD, ARIC 1996 to 2012
Degree of atherosclerosis Subjects at risk Incidence rate, 95% CI (per 1,000 person-years)
Minimal 1,708 3.82 (3.12, 4.68)
Mild 5,366 8.24 (7.60, 8.93)
Substantial 1,053 18.94 (16.68, 21.52)
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